Recommendations on data sharing in HIV drug resistance research

by Seth C. Inzaule, Mark J. Siedner, Susan J. Little, Santiago Avila-Rios, Alisen Ayitewala, Ronald J. Bosch, Vincent Calvez, Francesca Ceccherini-Silberstein, Charlotte Charpentier, Diane Descamps, Susan H. Eshleman, Joseph Fokam, Lisa M. Frenkel, Ravindra K. Gupta, John P.A. Ioannidis, Pontiano Kaleebu, Rami Kantor, Seble G. Kassaye, Sergei L. Kosakovsky Pond, Vinie Kouamou, Roger D. Kouyos, Daniel R. Kuritzkes, Richard Lessells, Anne-Genevieve Marcelin, Lawrence Mbuagbaw, Brian Minalga, Nicaise Ndembi, Richard A. Neher, Roger Paredes, Deenan Pillay, Elliot G. Raizes, Soo-Yon Rhee, Douglas D. Richman, Kiat Ruxrungtham, Pardis C. Sabeti, Jonathan M. Schapiro, Sunee Sirivichayakul, Kim Steegen, Wataru Sugiura, Gert U. van Zyl, Anne-Mieke Vandamme, Annemarie M.J. Wensing, Joel O. Wertheim, Huldrych F. Gunthard, Michael R. Jordan, Robert W. Shafer Author summary  • Human immunodeficiency virus (HIV) drug resistance has implications for antiretroviral treatment strategies and for containing the HIV pandemic because the development of HIV drug resistance leads to the requirement for antiretroviral drugs that may be less effective, less well-tolerated, a nd more expensive than those used in first-line regimens.  • HIV drug resistance studies are designed to determine which HIV mutations are selected by antiretroviral drugs and, in turn, how these mutations affect antiretroviral drug susceptibility and response to future antiretroviral treatmen t regimens.  • Suc...
Source: PLoS Medicine - Category: Internal Medicine Authors: Source Type: research